BioRestorative Therapies, Inc.

Listed Company

BRTXCIK 0001505497NasdaqNon-AcceleratedSmaller ReportingServices-Misc Health & Allied Services, NecNevadaFY ends Dec 31

Period

FY 2025

Revenue

$359.7K

Net Income

$-14.20M

Total Assets

$4.08M

Equity

$356.7K

Shares Out

25.48M

Op. Cash Flow

$-10.80M

BRTX$0.34−78.77% · past yearDBEQ Basic

Daily closing prices

Business

BioRestorative Therapies develops regenerative cell therapy products using adult stem cells. The company's lead program, BRTX-100, is an autologous mesenchymal stem cell product in Phase 2 clinical trials for chronic lower back pain from degenerative disc disease. The company also pursues the ThermoStem Program, a preclinical brown adipose tissue therapy for obesity and metabolic disorders, and operates a commercial biocosmeceuticals business selling cell-secretome skincare products. The company distributes investigational products through its own cGMP-certified laboratory and intends to license technology to third parties.

Summary from 10-K filed 2026-03-26

Financials

Consolidated Statement of Income

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Revenues	359,700	401,000	145,800	119,800	46,000
Cost of goods sold	23,844	28,072	—	—	—
Gross profit	335,856	372,928	145,800	—	—
Research and development	10	7	4	4	729,058
General and administrative	6	5	11	16	26
Total Operating Expenses	16	12	15	19	26
Loss From Operations	−16	−12	−15	−19	−26
Interest income, net	266,207	616,077	552,293	−11,650	2
Other income	17,448	150,850	169,664	−107,088	—
Gain on exchange of warrants	—	2	—	—	—
Change in fair value of warrant liabilities	1	97,188	4	—	—
Total Other Income	1	3	5	−479,256	18
Net Loss	−14	−9	−10	−18	−44
Net Loss Per Share - Basic	−1.58	−1.16	−2.47	−5.11	−37.3
Net Loss Per Share - Diluted	−1.58	−1.16	−2.47	−5.11	—
Weighted Average Common Shares Outstanding - Basic	9	8	4	4	1
Weighted Average Common Shares Outstanding - Diluted	9	8	4	4	—

Consolidated Balance Sheet

As of · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Cash and cash equivalents	2	547,890	884,377	2	21
Investments held in marketable securities	1	10	10	13	—
Accounts receivable	15,500	188,400	19,300	16,000	5,000
Prepaid expenses and other current assets	168,440	223,230	305,231	363,082	436,181
Total Current Assets	3	11	11	15	21
Deferred offering costs	49,808	148,697	—	—	—
Property and equipment, net	358,767	362,936	356,055	261,003	37,993
Intangible assets, net	534,198	623,945	713,692	803,438	589,740
Total Assets	4	12	13	16	22
Accounts payable	1	483,070	189,389	170,902	50,827
Accrued expenses and other current liabilities	982,047	744,485	—	—	—
Warrant liabilities	1	3	2	6	—
Total Current Liabilities	4	4	3	440,302	363,822
Commitments and contingencies	—	—	—	—	—
Common stock, $0.0001 par value; 75,000,000 shares authorized; 8,876,242 and 6,919,919 shares issued and outstanding at December 31, 2025 and 2024, respectively	887	692	471	369	353
Additional paid-in capital	170	164	157	168	156
Accumulated deficit	−170	−156	−147	−153	−134
Total Stockholders Equity	356,744	9	10	10	22
Total Liabilities and Stockholders Equity	4	12	13	16	22

Consolidated Statement of Cash Flows

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Depreciation and amortization	209,985	189,056	165,735	120,545	—
Dividend and interest income	−270,573	−623,801	−569,068	−76,004	—
Stock-based compensation	3	3	8	13	23
Non-cash lease expense	—	151,447	90,313	160,122	116,044
Accounts receivable	172,900	−169,100	−3,300	−11,000	12,000
Prepaid expenses and other current assets	101,770	33,591	57,851	73,099	−330,774
Accounts payable	839,525	293,680	18,487	120,075	−68,024
Accrued expenses and other current liabilities	195,281	32,799	581,616	−4,898	812,673
Lease Liability	—	−162,317	−139,328	−163,132	−101,190
Net Cash Used In Operating Activities	−11	−8	−6	−6	−3
Sale of marketable securities	12	22	21	9	—
Purchase of marketable securities	−3	−21	−18	−22	—
Purchases of equipment	−116,069	−106,189	−171,043	−265,223	−30,658
Net Cash Provided By Investing Activities	9	514,529	3	−13	−30,658
Payment of issuance costs	−177,953	—	—	—	—
Exercise of stock options	41,165	—	—	—	—
Proceeds from exchange and issuance of warrants, net	—	8	—	—	—
Payment of deferred offering costs	−99,973	−148,697	—	—	—
Repayment of financed insurance premiums	−4,698	—	—	—	—
Net Cash Provided By Financing Activities	3	7	2	—	21
Net Increase (Decrease) In Cash and Cash Equivalents	963,298	−336,487	−829,395	−19	18
Interest	—	—	—	—	—
Income taxes	—	—	—	—	—
Return and cancellation of shares in lieu of payroll tax withholding	—	48,410	39,308	—	—
Issuance of common stock held in abeyance	28	15	—	—	—
Reclassification of deferred offering costs	217,762	—	—	—	—
Deferred offering costs included in accounts payable	18,900	—	—	—	—
Financing of insurance premiums	46,980	—	—	—	—

Filings

Filing historySign up free to browse every 10-K, 10-Q, 8-K, and proxy this filer has submitted to the SEC.Sign up free · Upgrade to Pro

Material Events

Material EventsTrack every 8-K filing and material event — AI-summarized, timelined, and alertable.Sign up free · Upgrade to Pro

Insiders

Insider ActivitySee executive buy/sell windows and insider trade activity over rolling 30/90/365-day windows.Sign up free · Upgrade to Pro

Institutional Holders

Institutional HoldersSee which funds hold this stock and track position changes quarter over quarter.Sign up free · Upgrade to Pro

Frequently asked questions

What is BioRestorative Therapies, Inc.'s CIK number?

BioRestorative Therapies, Inc.'s SEC CIK number is 0001505497 (1505497). The CIK (Central Index Key) is the permanent identifier the SEC assigns to every EDGAR filer — unlike a ticker symbol, it never changes.

Where can I find BioRestorative Therapies, Inc.'s SEC filings?

All of BioRestorative Therapies, Inc.'s EDGAR filings — 10-K annual reports, 10-Q quarterly reports, 8-K material events, and insider transactions — are listed on this page, sourced live from SEC EDGAR.

When did BioRestorative Therapies, Inc. last report earnings?

BioRestorative Therapies, Inc. (BRTX) most recently filed an earnings 8-K with the SEC on Nov 12, 2025, furnishing its results under Item 2.02 (Results of Operations and Financial Condition). The earnings press release is attached to that filing (accession 0001021771-25-000148). This is BioRestorative Therapies, Inc.'s most recent earnings filing of record — not a forecast of its next earnings date.

What is BioRestorative Therapies, Inc.'s most recent earnings 8-K?

BioRestorative Therapies, Inc.'s latest earnings 8-K (Item 2.02) was filed Nov 12, 2025 under accession 0001021771-25-000148. It carries the quarterly or annual earnings press release — the earliest official, SEC-filed version of the results.

View BioRestorative Therapies, Inc.'s latest earnings 8-K →
Look up any company's CIK number →